Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc (GSK) covers the period ending May 2013. The report details a specific share repurchase transaction executed on May 20, 2013, following shareholder authorization granted at the Annual General Meeting on May 1, 2013.
Key Financial Metrics
The filing does not provide revenue, profit, cash flow, margin, debt, or liquidity metrics. It focuses exclusively on capital structure and share repurchase activity.
- Shares Purchased: 466,000 Ordinary Shares of 25 pence each.
- Price Range: Highest price paid was 1,724.5 pence per share; lowest price paid was 1,713.0 pence per share.
- Treasury Holdings (Settled): 499,315,913 shares (9.20% of total issued share capital).
- Treasury Holdings (Including Unsettled): 499,901,413 shares (10.15% of total voting rights).
- Shares in Issue (Excluding Treasury): 4,927,218,389 shares.
Material Changes
The primary material change reported is the reduction of outstanding shares through the purchase of 466,000 shares for Treasury. Consequently, the percentage of total voting rights held in Treasury increased to 10.15% when including unsettled purchases.
Guidance, Outlook, and Risks
The filing contains no forward-looking guidance, management commentary on operational outlook, or discussion of risks and contingencies. It is a compliance disclosure confirming conformity with the Financial Services Authority's Disclosure and Transparency Rules.
Investor Verification Checklist
- Verify the total number of shares held in Treasury against the latest quarterly or annual report to confirm the 9.20% to 10.15% range.
- Confirm the total issued share capital denominator (4,927,218,389 shares excluding Treasury) for calculating ownership thresholds under Disclosure and Transparency Rules.
- Check subsequent filings to determine if the unsettled shares mentioned in the report were fully settled.